BioSpace News Archive

Karuna Therapeutics, Inc. announced that data from the EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials evaluating KarXT in schizophrenia will be presented at the American Society of Clinical Psychopharmacology Annual Meeting being held from May 30, 2023 to June 2, 2023 in Miami, Florida.

Milestone Pharmaceuticals Inc. today announced promising data from an ad hoc analysis of a subset of patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) in the NODE-303 study, which evaluated etripamil, the Company’s investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).

Orlucent, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s Orlucent® Skin Fluorescence Imaging System.

Exscientia plc (Nasdaq: EXAI) today announced two abstracts for oral and poster presentation, as well as the closing keynote to be delivered at the Society for Laboratory Automation and Screening (SLAS) Europe Conference and Exhibition being held May 22-26, 2023, in Brussels, Belgium.

Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock.

Viatris Inc. Robert J. Coury will once again transition his role, this time from his current position of Executive Chairman to Chairman Emeritus and Senior Strategic Advisor to the board and management following the company’s 2023 annual meeting of shareholders.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that FLT201 has been awarded the Innovation Passport for the treatment of Gaucher disease type 1 under the Innovative Licensing and Access Pathway (ILAP) process by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

Processa Pharmaceuticals, Inc. today announces CEO David Young, Pharm.D., Ph.D. will participate in a panel at the World Orphan Drug Congress to be held at the Gaylord National Resort & Convention Center in Washington, D.C. May 23-25, 2023.

Rhythm Pharmaceuticals, Inc. announced a collaboration with Genpharm Services FZ LLC to commercialize IMCIVREE® in Gulf Cooperation Council countries, including Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman and Bahrain.

Poseida Therapeutics, Inc. today announced that two abstracts have been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), being held in Montreal, Canada and virtually on June 24-28, 2023.